No Data
No Data
Shandong Buchang Pharmaceuticals (603858.SH): won the second prize of National Science and Technology Progress Award.
On June 24, 2024, the National Science and Technology Awards Conference for the year 2023 was held in Peking. Shandong Buchang Pharmaceuticals Co., Ltd., and Director Zhao Tao participated in the "key technology and application of research mode on classic prescription and formula compatibility Taboo rules and compatibility rules of traditional Chinese medicine" project, which won the second prize of the National Science and Technology Progress Award for 2023.
Shandong Buchang Pharmaceuticals (603858.SH) has cumulatively repurchased 2.01% of its shares, with a capital expenditure of 358 million yuan.
Shandong Buchang Pharmaceuticals (603858.SH) announced that as of June 17, 2024, the company has traded through centralized bidding...
Shandong Buchang Pharmaceuticals (603858.SH) plans to increase the amount of share repurchases to 360-720 million yuan.
Shandong Buchang Pharmaceuticals (603858.SH) has issued an announcement to promote the recognition of the company's future development and value based on confidence.
Shandong Buchang Pharmaceuticals (603858.SH) has cumulatively repurchased 1.97% of its shares, costing 351 million yuan.
Zhìtōng Cáijīng APP reported that Shandong Bùcháng Pharmaceuticals (603858.SH) announced that as of May 31, 2024, the company has repurchased a total of 21.7875 million shares of the company through centralized bidding trading, and the repurchased shares account for 1.97% of the company's total share capital. The highest purchase price was 17.44 yuan / share and the lowest purchase price was 14.16 yuan / share. The total amount paid so far is 351 million yuan (excluding transaction costs).
Buchang Pharmaceutical (603858.SH): Holding subsidiary Qionglai Tianyin plans to increase capital and expand shares to implement equity incentives
Gelonghui, May 31, 丨 Buchang Pharmaceutical (603858.SH) announced that the company's holding subsidiary Qionglai Tianyin plans to implement equity incentives for Qionglai Tianyin's senior management and key employees in the form of capital increases and share expansion. The aforementioned incentive targets intend to participate in this equity incentive by directly holding shares in Qionglai Tianyin. The company agreed to relinquish priority payment rights. After the transaction was completed, the company's shareholding ratio in Qionglai Tianyin was changed from 92.75% to 91.3793%. The registered capital of Qionglai Tianyin increased from RMB 20 million to RMB 203 million. Qionglai Tianyin is still a holding subsidiary within the scope of the company's consolidated statements
Shandong Buchang Pharmaceuticals Gets China Nod for Cholesterol Control Tablets
China's medical products administrator approved Shandong Buchang Pharmaceuticals' (SHA:603858) ezetimibe 10 milligram tablets for high cholesterol, according to a Wednesday filing with the Shanghai St
No Data